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materials and helps to dissolve the protein, but they are
not quite inert to the protein, as are the polar organic
BIODEGRADABLE MICROSPHERES AS A
solvents used for casting from PHEMA and PVA. An
CARRIER FOR MACROMOLECULES
other disadvantage associated with these types of de
This application is a continuation of application Ser. 5 vices is the need for surgical insertion and eventually
surgical removal of the implant. This is necessary since . No. 07/152,843, ?led Feb. 5, 1988, now abandoned,
the devices are composed of materials which are nonde
which is a divisional of application Ser. No. 06/864,147,

gradable.

?led May 16, 1986, now U.S. Pat. No. 4,741,872.

Microspheres containing proteins have been prepared

BACKGROUND OF THE INVENTION

from polyacrylamide,

biodegradable polymers for the controlled release of
biologically active agents therefrom. More particularly,
the present invention relates to a process for preparing

biodegradable polymers in the form of spherical parti
cles of controlled size. The process is designed to allow

the biodegradable polymer particles to contain incorpo
rated biologically active agents and to allow controlled

release of these agents while allowing targeted delivery

acryloylated dextran and

acryloylated starch. Polyacrylamide beads can meet
different purposes in vitro, but their nondegradability
prevents their use in humans. Reported data on polysac
charide particles show that an ef?cient crosslinking has
been achieved only at a high degree of derivatization
(D.D. about 0.1 to 0.3). A high DD. is disadvantageous
as it decreases the biocompatibility of the polymer. A
high D.D. also leads preferentially to the intramolecular
reaction of polymerizable groups instead of the inter

(1) Field of the Invention
The present invention relates generally to the ?eld of

20

via injection or inhalation.

(2) Background of the Prior Art
The use of proteins and peptides as therapeutic agents
has been recognized and their position within the phar
maceutical armamentarium is growing due to their in

creasing availability. This availability is primarily due
to recent advances in genetic engineering and biotech

molecular reaction between different polymer chains,
which results in a heterogenous microporous structure.
The use of the crosslinking agent bisacrylamide is not
considered desirable, since it generally results in the

formation of crosslinked hydrocarbon gels, which nei
ther dissolve nor degrade even after degradation of the

polysaccharide component.

The recent advances in the incorporation of drugs
into microparticulate carriers has attracted a great deal
of attention because it combines features of matrix-con
30
trolled release with those of injectable forms. In addi
enteral routes of administration, i.e., oral and percutane
tion to controlled release, these microspherical carriers

nology. Unfortunately, the use of proteinaceous drugs
by conventional routes of administration is generally
hampered by a variety of delivery problems. Nonpar

ous, are inefficient primarily due to poor absorption of

proteinaceous drugs into the bloodstream and degrada
tion of such drugs in the gastrointestinal tract. Rapid

proteolytic inactivation of the proteinaceous drug also
occurs when the drug is administered parenterally thus
decreasing its bioavailability. In addition, when admin
istered by the parenteral route, the host’s immune sys
tem is activated thereby potentially setting off a series of
undesirable immune reactions.
In view of the foregoing, considerable effort has been
devoted to developing alternative systems for paren

teral delivery of peptides and proteins to obviate the
problems associated with prior art administration tech
niques. For instance, implantable devices have been cast
or molded from poly-(hydroxyethyl)methacrylate, pol

yvinyl alcohol,

ethylene-vinylacetate copolymer

(EVA) and silicone elastomer. Macromolecular drugs
have been embedded in those devices. A typical method
of preparation involves suspending a powder of a mac
romolecular drug such as a solid protein or peptide in a

solution containing the polymer. The entire composi
tion is then cast or molded into the desired size and

offer “first stage” physical targeting, that is, physical
localization of the drug carrier in the proximity of the
target tissue and cells. Localized administration of the
therapeutic agent allows for not only more efficient

drug therapy but also minimizes the opportunity for
adverse systemic effects.
In preparing microspheres in the size range of 1 pm
to 20 um, homogenous systems are more suitable than

heterogenous systems for casting implants. In the ho
mogenous system, proteins are co-dissolved in the same

solvent as the material of the matrix. Furthermore, in
order to preserve the biological activity of the macro

molecules, aqueous systems are generally preferred. In
this regard, biodegradable hydrophilic polymers can be
chosen as matrix material provided that they can be
solidi?ed or crosslinked by a mechanism which does
not involve a chemical modi?cation and/or denatura
tion of the incorporated macromolecule such as a pro

teinaceous agent.
It is known that crosslinked hydrophilic gels can be

obtained utilizing techniques of free-radical polymeriza

shape either by evaporating the solvent or by vulcaniza

tion. To some extent, the problems identi?ed above are

tion. A sustained release of macromolecules from these
devices has been demonstrated. The simplicity of the

gradable polymers, that is, polymers containing vinylic

similar to those found in the preparation of graft biode

mers such as those prepared from EVA and silicon, is

groups with the encapsulation of biologically active
materials therein.
Examples of prior art patents include U.S. Pat. Nos.

can be released. Thus, the drug present nearer the inte

properties of the polysaccharides within each composi

foregoing prior art method is its primary advantage.
However, one disadvantage of hydrophobic poly’

that those polymers are not permeable to hydrophilic 60 4,131,576, 3,687,878, 3,630,955 and 3,950,282. These
patents disclose methods for the preparation of graft
macromolecules, thus, only that portion of the drug
copolymers of polysaccharides and vinylic monomers.
which communicates with the surface of the implant,
These patents were directed to improving the physical
either directly or via contact with other drug particles,

rior of the implant and completely surrounded by the
polymer matrix is unable to ever be released and never

exerts its therapeutic effect. Addition of polar additives
increases penetration of water in these hydrophobic

tion. Process conditions used to achieve these improve
ments included the use of elevated temperatures, highly
reactive monomers or organic solvents. However, each
of the foregoing parameters are harmful to biologically

3
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active macromolecules and thus are unsuitable in the

practice of the present invention.
The prior art also discloses procedures for encapsula
tion of a core material in a polymer capsule. U.S. Pat.

No. 4,382,813 discloses the production of a capsule wall
by the gelation of polysaccharide gums, such as alkali
metal alginates, with bivalent metal cations. U.S. Pat.
No. 4,344,857 discloses the gelation of xanthates of

polyhydroxy polymers by the addition of strong acids
and coupling agents. U.S. Pat. No. 3,567,650 achieves a

similar result by lessening the solubility of certain poly
meric materials using increasing temperature.

4

It is another object of this invention to provide for a

matrix, containing pharmacologically active macromol
ecules, in the form of spherical particles of controlled
size, preferably having a diameter in the range of about
0.5 pm to about 500 pm.
It is also an object of this invention to produce micro- . .

spherical carriers from which macromolecular agents
are released under in-vivo conditions at a predictable
rate.

,_

It is yet another object of this invention to produce
microspherical carriers of biologically active macro
molecules which possess a potential for controlling the

plex coacervation using at least two colloids of opposite

rate of biodegradation of the matrix so that the release
of the macromolecular agents can be regulated by the

electrical charge and oxidation products of polysaccha

biodegradation of the matrix.

rides as crosslinking agents as disclosed in U.S. Pat. No.

A further object of the present invention is to pro
duce microspherical carriers of biologically active mac
romolecules which possess a potential for controlling
the rate of biodegradation of the matrix by adjusting the

Other mechanisms are based on the principle of com-I

4,016,098. Yet another procedure employs interfacial
crosslinking of the wall-forming polymer by reactive
bifunctional crosslinking agents dissolved in oil droplets

which are encapsulated as taught in U.S. Pat. No.
matrix properties thereby controlling both release of the
macromolecular agent and existence of the matrix in the
4,308,165. Other examples of the prior art which offer
tissue as well as assuring the biodegradation of the ma
similar teachings include U.S. Pat. Nos. 4,078,051,
trix into nontoxic soluble products which are metabo
4,080,439, 4,025,455 and 4,273,672. Materials which are
encapsulated according to the prior art are mostly
lized and/or excreted.
25
A still further object of the present invention is to
water insoluble solids or oil droplets and compounds
dissolved therein, e.g., dyes, pigments or biologically
provide a microspherical drug delivery system which
active low-molecular-weight compounds like herbi
allows targeting of drugs or other agents to speci?c host
cides.
tissues or cells via injection or inhalation providing high
U.S. Pat. No. 4,352,883 teaches a method for encap
sulation of core materials such as living tissues or indi
vidual cells in a semipermeable membrane. The mem

brane is permeable for small molecules but not permea‘
ble to large molecules. This patent also utilizes the gela
tion of certain water-soluble gums by the action of mul
tivalent cations.
U.S. Pat. No. 4,038,140 discloses the procedure for
binding of biologically active proteins onto an insoluble

carrier by reacting the proteins in an aqueous phase
with a carrier comprising an activated polysaccharide

having a hydrophilic graft copolymer incorporated
therein. That patent is directed to the preparation of

insoluble carriers containing covalently bound proteins
with application in biochemical reactors.

localized concentrations, sustained activity, systemic
administration and treatment, thereby minimizing unde
sirable systemic effects of toxic drugs administered di
rectly into the circulation.
These and similar objects, advantages and features
are accomplished according to the methods and compo

sitions of the following description of the present inven
tion.

-

BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 depicts an overall scheme for preparation of

the biodegradable microspheres of the present inven
tion.
FIG. 2 represents a more detailed view of the micro

sphere prepared by the process depicted in FIG. 1.
FIG. 3 depicts the cumulative release of alpha-l

Yet another example of the prior art,'U.S. Pat. No. 45
proteinase inhibitor from hydroxyethyl starchpolya
4,094,833, teaches a procedure for preparation of
copolymerizates of vinylic group containing dextran
crylamide microspheres in pg of protein per mg of

and divinyl compounds, optionally also monovinyl
compounds, in the form of three-dimensional gel net

works. The resulting crosslinked dextran-vinylic gels
can be used for separation purposes.

In spite of the numerous teachings of the prior art, the

microspheres.

'

'

DESCRIPTION OF THE PREFERRED
EMBODIMENTS
The present invention provides a process for the

incorporation of sensitive biologically active macro
molecules into a biodegradable matrix. The biodegrad
such as proteinaceous agents in spherical microparticles 55 able matrix is prepared by the copolyrnerization of a
of controlled size ranges. Nor does the prior art suggest
vinyl derivative of biodegradable hydrophilic polymer
a procedure for allowing microspheres to have the
containing at least two vinyl groups per polymer chain
potential to control the rate by which the biologically
with a monovinyl water-soluble monomer. The biode
active macromolecule is released or for modulating the
gradable matrix is a three-dimensional gel network in
rate by which the matrix is degraded in vivo.
which biologically active macromolecules are physi
prior art does not offer a method for obtaining encapsu
lated or entrapped biologically active macromolecules

SUMMARY OF THE INVENTION

It is, therefore, the object of this invention to provide
a process for the incorporation of sensitive biologically

active macromolecules, preferably peptides and prote
ins, into a biodegradable and biocompatible matrix
under conditions sufficiently mild to retain the biologi
cal activity of the incorporated macromolecular agents.

cally entrapped. The biodegradable matrix is particu
larly well-suited for the parenteral route of administra
tion.

According to the present invention, the biodegrad
65 able hydrophilic polymer component of the matrix can

be selected from a variety of sources including polysac

charides, proteinaceous polymers, soluble derivatives of
polysaccharides, soluble derivatives of proteinaceous

5,160,745
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polymers, polypeptides, polyesters, polyorthoesters,

6
lected biodegradable hydrophilic polymer containing

and the like.

either hydroxyl or amino groups. In a like manner,
derivatives containing either ester or amide linkages can

The polysaccharides may be poly-1,4-glucans, e.g.,
starch glycogen, amylose and amylopectin, and the like.
Preferably, the biodegradable hydrophilic polymer is a
water-soluble derivative of a poly-1,4-glucan, including

be prepared by reacting acryloyl chlorides, methacryl
oyl chlorides, acryloyl glycidyl esters or methacryloyl
glycidyl esters with hydroxyl or amino groups of the

hydrolyzed amylopectin, hydroxyalky] derivatives of
hydrolyzed amylopectin such as hydroxyethyl starch
(HES), hydroxyethyl amylase, dialdehyde starch, and
the like.

Proteinaceous polymers and their soluble derivatives

biodegradable hydrophilic polymer.
The degree of derivatization (DD) of the biodegrad
able hydrophilic polymer by the vinyl groups is such,
10 that they are at leasttwo vinyl groups per average

polymer chain, preferably, at least three vinyl groups
per average polymer chain. The upper limit of DD is
given by the desired density of crosslinking as discussed

include gelation biodegradable synthetic polypeptides,
elastin, alkylated collagen, alkylated elastin, and the
like.

below. It should also be noted that the minimum DD,
when expressed in moles of vinyl groups per mole of

Biodegradable synthetic polypeptides include poly

(N-hydroxyalkyl)-L-asparagine, poly-(N~hydroxyalk

monomer units of biodegradable hydrophilic polymer

yD-L-glutamine, copolymers of N-hydroxyalkyl-L

also depends on the molecular weight of the biodegrad

asparagine and N-hydroxyalkyl-L-glutamine with other

able hydrophilic polymer.

amino acids. Suggested amino acids include L-alanine,

The monovinyl monomer has two functions. First, it
is intended to facilitate the propagation reaction of the

L-lysinc, L-phenylalanine, L-leucine, L-valine, L-tyro
sine, and the like.
De?nitions or further description of any of the fore
going terminology are well known in the art and may be
found by referring to any standard biochemistry refer

growing radical by lessening steric hindrance during
the polymerization of the macromolecular vinyl deriva
tives. This obviates the necessity of a high degree of

ence text such as “Biochemistry” by Albert L. Lehn

derivatization of the starting biodegradable hydrophilic

inger, Worth Publishers, Inc. and “Biochemistry” by

polymer. And second, it is intended to introduce into
the gel structure or matrix a nondegradable component

Lubert Stryer, W. H. Freeman and Company, both of
which are hereby incorporated by reference.

which can participate in the regulation of the degrada

The aforementioned biodegradable hydrophilic poly

tion rate of the matrix.
The ratio of the monofunctional monomer propaga
mers are particularly suited for the methods and compo 30
sitions of the present invention by reason of their char
tor to derivatized biodegradable hydrophilic polymer is

acteristically low human toxicity and virtually com
plete biodegradability. Of course, it will be understood

chosen such, that during the polymerization, short lin
ear chains of hydrocarbon polymers are produced
which are in fact crosslinked by degradable hydrophilic
polymer chains. This assures that substantially the en

that the particular polymer utilized is not critical and a

variety of biodegradable hydrophilic polymers may be
utilized as a consequence of the novel processing meth
ods of the invention.
The three dimensional network or gel matrix accord
ing to the present invention is obtained by the free-radi

tire matrix of microspheres can be degraded in vivo to

low molecular weight soluble products.
The ratio between the biodegradable hydrophilic
polymer component to the vinyl monomer component

cal polymerization of the biodegradable hydrophilic

may be in the range of about 1:5 up to about 40:1 based
on a weight basis. Preferably, the ratio is in the range of
about 2:1 to about 20:1.
The monovinyl monomer is designed to facilitate the

polymer containing at least two vinyl or substituted
vinyl groups with an additional monovinylic monomer.

The vinyl derivatives of the biodegradable hydro
philic polymer include derivatives containing groups of
the formula (I):
CH2:CR1-—(CH2),,—X

45

(I)

propagation reaction of the growing radical during
polymerization thereby obviating the necessity of high
derivatization of starting polysaccharide with polymer~
izable groups. The monovinyl monomer also introduces

in the polymer matrix other functional groups, e.g.,

wherein R1 is a hydrogen atom or methyl group; n is 0,
l or 2; and is a radical having the formula

negatively or positively charged, which can participate
in the control of drug release. Typical functional groups
which may participate in the control of drug release

include carboxyl, amino, dialkylamino, dihydroxyalk
ylamino, and the like. The presence of these positive or

wherein R2 represents the above-mentioned biodegrad

55

the matrix.

able polymer which contains at least two vinyl or sub

stituted vinyl groups per average polymer chain. Thus,
bridge between the group of formula (I) and the biode
60

The vinyl derivatives of the biodegradable hydro
philic polymer can be prepared in a variety of ways well
known in the prior art. One suggested approach is the 65

preparation of vinyl and allyl ethers by the reaction of
vinyl alkylhalides, allylhalides, vinylglycidyl ethers or
allylglycidyl ethers with alkaline solutions of the se

,

The monovinyl monomer may be selected from the
group of hydrophilic esters and/or amides of acrylic or

X represents an ether, secondary amine, ester or amide

gradable hydrophilic polymer. Therefore, typical exam
ples of vinyl substituents include vinyl, allyl, acryloyl,
methacryloyl, acrylamido and methacrylamido groups.

negative charges provide ion-exchange properties to

methacrylic acids, water-soluble vinyl derivatives,
acrylic acid, methacrylic acid, and the like. Typical
examples of hydrophilic esters and/or amides of acrylic
or methacrylic acids include acrylamide, methacrylam

ide, Z-hydroxyethyl methacrylate, Z-hydroxypropyl
methacrylamide, N-methylacryloyl-trishydroxyme

thylaminomethane,
N-acryloyl-N’-dimethylamino
propylamine, 3-N,N-dimethylaminopropylmethacryla
mide, N-alkylmethacrylamide glyceryl monomethacry
late, and the like. Suitable water-soluble vinyl deriva

7

5,160,745

tives include N-vinylpyrrolidone, N-vinylimidazole,
p~vinylbenzoic acid, vinylpyridine, and the like.

8

invention that the monovinyl monomer have a molecu

clude hormones, proteins, peptides, vaccines, enzymes,

lar weight of less than 400.
The drug delivery system in accordance with the
present invention is ideally suited for administration by
parenteral or inhalation routes. It will be appreciated by

enzyme inhibitors and other biologically active macro

those skilled in the art that the porous microspheres of _ .

Suitable biologically active macromolecules intended
to be used in the practice of the present invention in

molecules. A suggested inhibitor is alpha-l-antitrypsin
(ATT), an a-proteinase inhibitor. Additional examples
include amino acid metabolizing enzymes in the treat

ment of neoplasia, ?brinolytic enzymes, interferon,

growth hormone, antigens for desensitization, immuno
globulins and Fab-fragments of immunoglobulins. The

the present invention containing incorporated drugs for
release to target cells or tissues, therefore, may be ad
ministered alone or in admixture with appropriate phar
maceutical diluents, carriers, excipients or adjuvants
suitably selected with respect to the intended route of
administration and conventional pharmaceutical prac

present invention is not intended to be limited to any of

tices. These inert pharmaceutically acceptable adju

within the polymer matrix, that is, there are no chemical

suitable sterile aqueous or non-aqueous solutions or

vants are well known in the art. For example, for paren
the foregoing and other types of biologically active
teral
injection, dosage unit forms may be utilized to
15
macromolecules are equally suitable in the practice of
accomplish intravenous, intramuscular or subcutaneous
the present invention.
administration, and for such parenteral administration,
The biologically active macromolecules remain free
bonds between the macromolecule or some other group

within the microsphere. Thus, the macromolecule does
not require the breakage of a chemical bond to be re
leased. Release occurs through diffusion out of the mi

crosphere or biodegradable erosion of the polymer.
The polymerization reaction according to the present
invention is conducted under suitable conditions for
free radical polymerization. The reaction is always con
ducted in aqueous solution. Suitable free radical initia
tors are redox type initiators. The polymerization reac

tion is preferably conducted using free radical initiators
to produce free radicals under mild conditions such as a

temperature of approximately 0° C. However, the tem
perature of the polymerization reaction may range from
about 0'’ C. to about 50° C. The preferred temperature
at which to conduct the polymerization reaction ranges
from about 0° C. to about 30° C.
It is a particularly advantageous feature of the present

manufacturing procedure that, starting from the disso

suspensions, optionally containing appropriate solutes
to effect isotonicity, will be employed. Likewise for
inhalation dosage forms, for administration through the
mucous membranes of the nose and throat or bronchio

pulmonary tissues, suitable aerosol or spray inhalation
compositions and devices will be utilized.

The foregoing methodology allows for the prepara
tion of microspheres in controlled size ranges under
conditions sufficiently mild to preserve the biological
activity of functional macromolecules. In addition, the

foregoing methodology allows for the potential for
controlling the release of the drug by controlling the
crosslinking density and the rate of degradation via
selecting the derivatization degree of the starting poly
saccharide and matrix composition.
The polymerization may be conducted by any poly
merization process known in the art, however, another
important feature of the present invention is the fact
that the polymerization can be conducted using a bead

polymerization technique. According to the convenient

lution of the macromolecule of interest until dispensing
process described in the present invention, the deriva
the ?nal microspheres in vials, the entire process can be 40 tized biodegradable hydrophilic polymer, the monovi
carried out at temperatures near 0° C. in order to mini
nyl monomer and the biologically active macromole
mize the denaturation effect on the macromolecule.

Typical redox type initiators include ammonium persul

fate, hydrogen peroxide, benzoyl peroxide, and the like.
It is also advantageous to use a free radical initiator

along with a compound which forms with the initiator
a redox system and accelerates the formation of radi
cals. Examples of the second compound of the initiator

system include N,N,N’N’-tetramethylethylenediamine,
ascorbic acid, N,N-dimethylamino-p-toluidine, 3-dime
thylarninopropionitrile, sodium metabisul?te, and the
like.

During the polymerization reaction, linear chains of
vinylic polymer are formed which are cross-linked with

the biodegradable hydrophilic polymer. It is thus im
portant that a monovinyl monomer is used during the I

polymerization reaction to ensure that only linear

chains of nondegradable hydrocarbon polymers are
formed. Thus, the use of the monovinyl monomer en

cule which is to be incorporated therein are codissolved

in an aqueous buffer of appropriate pH and ionic

strength which is suitable for preserving the biological
activity of the macromolecular agent, usually together
with one component of the initiator system. Either oxi
dative or reductive types of initiators are useful.

The aqueous solution is then deoxygenated by purg
ing with N2 and emulsified in a deoxygenated water

immiscible organic liquid, preferentially composed of
higher aliphatic hydrocarbons such as hexane, heptane,
octane, cyclohexane, or their higher homologs and their
mixtures. In order to facilitate the emulsification and
formation of a water-in-oil emulsion, appropriate emul
sifying agents are added to the continuous organic

phase. Typical emulsifying agents include sorbitan ole
ates, polyethylene glycol ethers, polyoxyethylene sorbi
tan esters, polyoxyethylene polyoxypropylene alcohols,

and the like.
sures that the degradation of the biodegradable compo 60 After obtaining an emulsion having a suitable size
nent which is responsible for the crosslinking will allow
range of aqueous droplets, the polymerization is begun
for the formation of totally soluble degradation prod
by addition of the other component of the initiator
ucts. The monovinyl monomer of the present invention,
system to the emulsion. When a water soluble com
since it is only a monomer, will have a low molecular
pound is used, the oxidant component of the initiator
- weight compared to the biodegradable polymer. It has 65 system, e. g., ammonium persulfate and the like, is in the
been speculated that if the molecular weight of the
aqueous dispersed phase, then the second component is
a reductant soluble in the continuous phase, e.g.,
monomer exceeds 400, then steric hindrance is possible.
N,N,N’,N’-tetramethylethylenediamine and the like.
Thus, it is recommended for purposes of the present

9
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The microspheres formed by the polymerization of the
aqueous droplets of the emulsion are cleansed by decan
tation and washed with an appropriate water-immisci
ble organic solvent and then freeze dried. Suitable or

ganic water-immiscible solvents include cyclohexane,
benzene, cyclohexanone, and the like.
Following another procedure according to the pres
ent invention, the microspheres after washing with
organic solvent can be redispersed in water or an aque

ous buffer, washed with the buffer and freeze-dried
from an aqueous suspension. The biologically active

10

starch (HES) is used as the starting biodegradable hy
drophilic polymer, the broad range of about 0.01 to
about 0.20 corresponds to a molecular weight of the

average segment between crosslinking points of about
20,000 to about 1000, respectively. About 0.02 to about
0.15 corresponds to a molecular weight range of the

average segment between the crosslinking points of
about 10,000 to about 1,800. The range in cross-linking
density of 0.02 to 0.15 moles of vinyl groups per moles
of monomer units will produce approximately a ten-fold
difference in the release rate of the protein having a

compound, e.g., peptide, protein, and the like, while
co-dissolved in the aqueous dispersed phase, is en
trapped in the crosslinked polymer network during
polymerization and can be released in vivo essentially
by the diffusion through the polymer network or fol
lowing the degradation of the matrix.
A particularly advantageous feature of the foregoing
process, and irrespective of the particular polymeriza

molecular weight of about 50,000.
It will be appreciated that the concentrations, tem

tion technique selected, is that the microspheres can be

order that those skilled in the art may more readily

prepared in a variety of size ranges generally ranging

understand the present invention and the speci?c pre
ferred embodiments thereof. Unless indicated other

from about 0.5 pm to about 500 pm in diameter. Size
ranges from about 1.0 pm to about 150 pm in diameter
are generally preferred. For inhalation administration a
microsphere size range of from about 1.0 um to about
5.0 pm in diameter is preferred. For injectable adminis
tration a microsphere size range of about 8.0 pm to
about 15.0 pm in diameter is preferred.

peratures and ratios referred to hereinabove and in the
examples set forth operable ranges and that other nu
merical expressions may apply as different solvents,
polymers, monomers, macromolecules, etc. are se
lected.

The following non-limiting examples are offered in

wise, all amounts are given in grams.

EXAMPLE 1
To a solution of hydroxyethyl starch (HES) (HES
PAN, a trademark of American Critical Care) in dry,

distilled N,N’-dimethylacetamide (DMAA) at approxi

The size of the resulting microspheres depends on the
mately 0° C., a measured amount of distilled acryloyl
size of the aqueous droplets in the water-in-oil emulsion. 30 chloride was added in small portions along with an
The size of the droplets in turn is dependent upon the
equimolar amount of triethylamine, over approximately
shear stress which is applied by the stirrer. The stirrer

a 30 minute time period. The reaction vessel was main

opposes the coalescing tendencies caused by surface
tained at this temperature and the reaction proceeded
tension. Generally, the size of the droplets is reduced by
for approximately 2 additional hours. The reaction mix
applying a higher shear stress. A higher shear stress is 35 ture was then transferred to a vessel containing 200 ml
achieved either by using a higher stirrer speed or by
of acetone at about 0° C. to about 5° C. to precipitate the
increasing the ratio between the viscosities of the con
polymer.
The polymer was washed with acetone, dried
tinuous phase and the dispersed phase. A higher viscos
with
air
suction,
dissolved in water and reprecipitated in
ity of the continuous phase may be achieved by increas
acetone. Derivatized HES (acryloyl-HES) was ?nally
ing the proportion of hydrocarbons with more carbon
atoms in the emulsion, e.g., octane, dioxane, dodecane

and the like. The viscosity of the aqueous dispersed
phase may be adjusted by using a different molecular

weight of the starting biodegradable hydrophilic poly

puri?ed by preparative gel permeation chromatography

in water and then freezedried. Ratios of the reactants

and the data on the resulting polymers are presented in
Table l. The symbol mwA represents the molecular

mer. Adjustment of the viscosity of the aqueous dis 45 weight equivalent of the biodegradable hydrophilic
persed phase in this manner allows for use of the same
total gel matrix and monovinyl monomer concentra
tion.

Another advantageous feature of the present inven
tion is the fact that the incorporated macromolecular
agents are released from the gel matrix by a diffusion

through the crosslinked hydrogel network. Various
rates of release of the macromolecular agents may be

achieved by varying the crosslinking density of the gel

polymer per vinyl group. D.D. represents the degree of
derivatization in millimole/gram.
TABLE I

Preparation of Acgyloyl-HES
HES
DMAA
Acryloyl chloride
Triethylamine

Acryloyl-HES (yield)
matrix. The crosslinking density of the matrix may be 55 DD.
(mmole/gram)

varied by selecting a biodegradable hydrophilic poly

mer with varying degrees of derivatization (DD). De

mwA

la

lb

1c

1d

5.0
18.8
0.1
0.1 l

5.0
18.8
0.2
0.22

5.0
18.8
0.4
0.45

5.0
18.8
1.0
1.1

4.3

4.3

4.6

5.]

. 0.07

0.17

0.26

0.62

14,300

6,000

3,800

1,600

grees of derivatization are used to indicate the average

distance between the attached vinylic groups. A suit
able crosslinking density is also dependent on the mo
lecular weight of the macromolecular agent and on the

EXAMPLE 2

Approximately 4.05 grams of partially hydrolyzed

desired rate of its release.

amylopectin was dissolved in 80 ml of water. The solu

philic starting polymer. Preferably, there are about 0.02

of NaOH so that the solution was remained alkaline.

tion was cooled to 0° C. and the solution of 1.8 grams of
The degree of derivatization is preferably in the range
acryloyl chloride in 10 ml of acetone was added in small
of about 0.01 to about 0.20 mole of vinyl groups per
mole of monomer units of the biodegradable hydro 65 portions during stirring along with 10 ml of 2 N solution

to about 0.15 mole of vinyl groups per mole of mono

After approximately 30 minutes the acryloyl-amylopec

mer units of the starting polymer. If hydroxyethyl

tin was precipitated with acetone and further processed

5,160,745
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was added to the emulsion and the reaction proceeded
at about 0° to 2° C. for another 20 minutes. The result

in a manner similar to Example 1. The yield was 3.9

grams and the DD. was 0.32 mmole/gram.

ing suspension of microspheres was poured in 200 ml of
cold heptane (0°-5° C.), washed with heptane, resus
Approximately 5.0 grams of HES was dissolved in 5 pended in ammonium carbonate buffer containing 0.1%
EXAMPLE 3

18.8 grams of DMAA and to this solution was added 6

of Triton-X-lOO, washed with pure ammonium carbon

ml of 2N solution of NaOl-l, 50 mg of 4-methoxyphenol

ate buffer (0.01 mole/liter) and freezedried.
TABLE II
Reaction conditions and-characteristics of the product
a

b

c

d

e

f

g

h

Acryloyl-HES
Acrylamide
Alpha-l-Pl
Buffer

1.76
0.40
0.34
17.50

1.76
0.40
0.34
17.50

1.76
0.40
2.20
15.60

2.00
0.50
0.60
16.90

2.00
0.50
0.60
16.90

2.00
0.50
0.60
16.90

2.00
0.50
0.60
16.90

2.00
0.50
0.60
16.90

mwA

3,800

6,000

3,800

3,800

6,000

6,000

6,000

6,000

17
43

17
43

17
43

17
43

17
43

17
43

40
20

10
50

Stirring

1,600

1,600

1,600

1,600

1100

2,200

2,200

2,200

Average diameter

8.6

14.0

12.5

7.6

28.0

5.8

46.0

3.6

4.7

4.5

22.8

9.4

—

-

-

—

m

Heptane (ml)
Mineral oil (ml)

(rpm)
(pm)

Protein content

%

and 1.4 grams of allylglycidyl ether. The resulting mix- 25
ture was stirred for 20 hours at room temperature and
then rocessed in a manner similar to Exam le 1. The

p
p
yield was 4.3 grams and the DD. was 0.42 mmole/
gram.
EXAMPLE 4

EXAMPLE 6
Example 6 was conducted in a manner similar to

Example 5, except that the product was washed with

heptane, then washed with cyclohexane and ?nally
freeze-dried from cyclohexane. The resulting micro
spheres exhibited properties analogous to those found in
Example 5 but contained essentially all of the protein
was reacted with 0.4 grams of acryloyl chloride in a
procedure similar to that used in Example 1. The yield 35 which had been initially added in the dispersed phase.

Approximately 4.3 grams of poly-[N-(Z-hydroxye
thyl)-L-glutamine], (PHEG), in 18.8 grams of DMAA

of acryloyl-PHEG was 4.2 grams and the DD. was 0.32

EXAMPLE 7

mmole/gram.

Approximately 1.6 grams of acryloyl-PHEG, pre
EXAMPLE 5
pared according to Example 4, 0.58 gram of N-vinyl-Z
Acryloyl-HES, prepared according to Example 1, 40 pyrrolidone and 0.49 gram of alpha-l-proteinase inhibi
tor (alpha-l-PI) in 13.5 ml of 0.05 mole/liter phosphate
acrylamide and alpha-l-proteinase inhibitor (alpha-l
PI) were dissolved in 0.05 mole/liter ammonium car

bonate buffer pH 7.4, together with ammonium persul

buffer pH 7.4 were used as a dispersed phase to prepare
microspheres in a manner similar to that set forth in

Example 5d. The resulting microspheres had an average
phate (2% mole/mole in terms of the total concentra
non of vinyl groups). The solution was deoxygenated 45 diameter of 6.7 pm and a protein content of 11.2%.
by repeated evacuation and ?lling of the vessel with
EXAMPLE 8
nitrogen at 0“ C. The deoxygenated solution was ?l
Approximately 50 mg of microspheres prepared in a
tered and the ?ltrate was transferred to a polymeriza
manner similar to that used in Examples 5a—a' were
tion reactor containing 60 ml of organic continuous

phase. The organic continuous phase was composed of 50 suspended in 10 ml 0.05 mole/liter phosphate buffer pH
7.4 with 0.15 mole/liter NaCl and 0.02% NaNg. The

a mixture of heptane, USP, mineral oil and 0.3 gram of
SO-lS (sorbitan oleate). The entire mixture was then
flushed with nitrogen at 0° C. Table II provides a de

suspensions were placed in capped test tubes and were
incubated at 37° C. with continuous agitation. Samples

of the suspensions were withdrawn at convenient inter
scription of the compositions of the dispersed and con
tinuous phases. In Table II, average diameter (pm) 55 vals and the microspheres were separated by centrifuga
tion. The residual amount of the protein in the micro
represents the average diameter of the microspheres
spheres, the concentration of protein in microspheres
after rehydration in 0.15 mole/liter NaCl and 0.05
and the concentration of protein in the incubation me
mole/liter phosphate pH 7.4. The protein content %
dium were determined using the method of Lowry et al.
represents the content of the diffusion releasable protein
in dry microspheres.
,
(0. H. Lowry et al., J. Biol. Chem, 193: 265, 1951). The
amount of alpha-l-PI released as function of time is
The polymerization reactor consisted of a jacketed
presented in FIG. 2. FIG. 3 describes the cumulative
glass vessel equipped with a controlled-speed stirrer.
release of alpha-l-PI from HES-polyacrylamide micro
Ports for addition of reactants and withdrawal of sam
spheres in pg of protein per mg of spheres. The incuba
ples as well as nitrogen inlet were provided in the ves

sel-top assembly. When a stable emulsion of the aqueous 65 tion time is plotted in a square root scale. Characteris
tics of microspheres are those as in Table 2. Characteris

dispersed phase in the organic continuous phase was
obtained by the action of the stirrer, approximately 0.15

tics of the microspheres corresponds to those given in

ml of N,N,N’,N'-tetramethylenediamine (TEMED)

Example Sa-d.
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and wherein R2 represents the biodegradable hydro

While this invention has been described and illus
trated with reference to certain preferred embodiments
thereof, those skilled in the art will appreciate that vari
ous changes, modi?cations and substitutions can be

philic polymer which contains at least two vinyl or

substituted vinyl groups per average polymer chain.
4. The porous microsphere according to claim 3,
wherein the biodegradable hydrophilic polymer is se
lected from the group consisting of polysaccharides,

made therein without departing from the spirit of the
proteinaceous polymers, soluble derivatives of polysac
invention. It is intended, therefore, that the invention be
charides, soluble derivatives of proteinaceous polymers,
limited only by the scope of the claims which follow.
polypeptides, polyester and polyorthoesters.
What is claimed is:
10
5. The porous microsphere according to claim 4,
1. A porous microsphere comprising a biodegradable
wherein the biodegradable hydrophilic polymer is a
polymeric structure having a three-dimensional poly
polysaccharide.
meric network in which a biologically active macromo
6. The porous microsphere according to claim 5,
wherein the polysaccharide is a starch derivative.
lecular agent is physically entrapped therein and not
7. The porous microsphere according to claim 4,
substantially bonded to the polymeric network, said
whereon
the biodegradable hydrophilic polymer is a
polymeric structure comprising a vinyl derivative of a

polypeptide.

biodegradable hydrophilic polymer copolymerized

8. The porous microsphere according to claim 7,

with a water-soluble monovinyl monomer, said macro
wherein the polypeptide is poly-(N-hydroxyalkyDas
molecular agent able to be released at a controlled rate 20 paragine or poly-(N-hydroxyalkyl)glutamine.

9. The porous microsphere according to claim 1,

by diffusion out of the pores and by degradation of the
polymeric structure.
2. The porous microsphere according to claim 1,
wherein said biodegradable hydrophilic polymer con

wherein the water-soluble monovinyl monomer is se

lected from the group consisting of hydrophilic esters
and/or amides of acrylic or methacrylic acids, water

soluble vinyl derivatives, acrylic acid and methacrylic

tains at least two vinyl groups or substituted vinyl

acid.

groups per average polymer chain.
3. The porous microsphere of claim 2, wherein the

.

10. The porous microsphere according to claim 1,
wherein the ratio between the biodegradable hydro
philic polymer to the water-soluble monovinyl mono

vinyl derivative of the biodegradable hydrophilic poly

30 mer is in the range of about 1:5 to about 40:1 on a weight

mer has the formula:

basis.

.

11. The porous microsphere according to claim 1,
wherein the biologically active macromolecular agent
is a hormone, protein, peptide, vaccine, enzyme or en
wherein R1 represents a hydrogen atom or methyl 35 zyme inhibitor.
group; n is 0, l or 2; X represents a radical having the
12. The porous microsphere according to claim 11,
formula:
whereon the biologically active macromolecular agent
CH2:CR|-—(CH2)n-——X

(I)

is a hormone.

13. The porous microsphere according to claim 1,
wherein the biologically active macromolecular agent
is a peptide.
#
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